# A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors

> **NCT04841538** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Elpiscience Biopharma, Ltd.**

## Conditions studied

- Thoracic Tumors
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer

## Interventions

- **DRUG:** ES101

## Key facts

- **NCT ID:** NCT04841538
- **Lead sponsor:** Elpiscience Biopharma, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07
- **Primary completion:** 2023-12
- **Final completion:** 2024-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor's clinical development strategy adjustment
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04841538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04841538, "A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04841538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*